Daniel Loftus, Ph.D.

Daniel Loftus is a Scientist in the mRNA Programming team at Strand Therapeutics. He currently applies NGS methods to support Strand’s platform development. Prior to joining Strand, he was an NGS Scientist at Intellia Therapeutics, focusing on genotoxicity analysis of gene editing products for regulatory filings. He earned his Ph.D. at Harvard University as a member of Amanda Whipple’s lab, where he studied the effects of allele-specific chromatin structure on imprinted gene expression, and his B.S. at the University of Texas at Austin as a member of Arlen Johnson’s lab, where he studied eukaryotic ribosome biogenesis.